MTOR and autoimmune disease: Due to autoimmune disease’s increasing prevalence and regarding the fact that immune metabolites could be recognized much earlier than symptom onset, detection of increased GLUT1 and high glycolysis-related genes and, therefore, targeting OXPHOS, mTOR, and/or glycolysis, could be considered a therapeutic approach to minimize the side-effects of the traditional immunosuppressant drugs.